THERAPEUTIC AREA
savePulmonology
Diseases of the lungs and respiratory tract.
also known as: respiratory, lung, pulmonary
🐶 often sniffed alongside
top 8- tagOncology207 co-mentions · 51 sources
- tagNSCLC108 co-mentions · 47 sources
- tagAdCom58 co-mentions · 53 sources
- tagRecall49 co-mentions · 33 sources
- tag510(k) Clearance35 co-mentions · 30 sources
- tagCardiology25 co-mentions · 17 sources
- tagPMA Approval23 co-mentions · 23 sources
- tagInfectious Disease21 co-mentions · 20 sources
drugs
396
catalysts
22
news
1,612
companies
278
Top drugs
view all →Marketed
CLEOCIN
$PFE · 127 catalysts
Marketedclindamycin hydrochloride
Bacterial Pneumonia
90 catalysts
MarketedNALBUPHINE HYDROCHLORIDE
Pain
84 catalysts
MarketedDOXYCYCLINE HYCLATE
$AMRX · 49 catalysts
Marketedmethylprednisolone sodium succinate
Drug Hypersensitivity Reactions
48 catalysts
MarketedMETHYLPREDNISOLONE ACETATE
Giant Cell Arteritis (Temporal Arteritis/Cranial Arteriti…
41 catalysts
MarketedMETRONIDAZOLE
Bacterial Endocarditis
36 catalysts
MarketedMEDROL
$PFE · 34 catalysts
🐶 Top companies
view all →Recent catalysts
view all →Apr 30, 2026
phase 2 completion
Huadong Hospital Affiliated to Fudan University — lidocaine (Phase II Trial Completion)
LIDOCAINE
→
Apr 30, 2026
phase 2 completion
$AZN156.90-0.51%
AstraZeneca Plc — tozorakimab (Phase II Trial Completion)
tozorakimab
→
Apr 30, 2026
phase 2 completion
$MRK144.30+0.34%
Merck & Co Inc — tulisokibart (Phase II Trial Completion)
tulisokibart
→
Apr 30, 2026
phase 2 completion
Brigham and Women's Hospital — dupilumab (Phase II Trial Completion)
dupilumab
→
Apr 30, 2026
phase 1 2 completion
Wuhan YZY Biopharma Co Ltd — M-701 (Phase I/II Trial Completion)
M-701
→
Apr 30, 2026
phase 1 completion
Beijing Minhai Biotechnology Co Ltd — pneumococcal (20-valent) vaccine (Phase I Trial Completion)
pneumococcal (20-valent) vaccine
→
Apr 30, 2026
phase 0 trial completion
Civil Aviation General Hospital — dexmedetomidine (Phase 0 Trial Completion)
dexmedetomidine
→
Apr 30, 2026
constraining patent expiry europe
$CPIX7.3900-1.60%
Cumberland Pharmaceuticals Inc — telavancin hydrochloride (Constraining Patent Expiry (Europe))
telavancin hydrochloride
→
Apr 29, 2026
phase 3 initiation
Chia Tai Tianqing Pharmaceutical Group Co Ltd — TQH-2722 (Phase III Trial Initiation)
TQH-2722
→
Apr 29, 2026
phase 2 initiation
Shenzhen Resproly Biopharmaceutical Co Ltd — RSN-0402 (Phase II Trial Initiation)
RSN-0402
→
Recent news
view all →- This week in charts: Kodiak’s big comeback and Hengrui’s dealmakingbiopharma dive · 1d ago
- BMO most bullish on Merck's, bearish on BMS’ plans to contend with patent cliffsbiospace · 1d ago
- Foghorn cuts 40% of workforcebiospace · 1d ago
- Varda raises $251M to leverage gravity in space for drug productionbiospace · 1d ago
- FDA Approves First Heart Valve Designed to Grow with Childrenfda press · 2d ago
- Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEOfiercebiotech · 2d ago
- Sanofi, Regeneron broaden alliance to find their next Dupixentbiopharma dive · 2d ago
- Merck’s antibody impresses with ‘highly competitive’ data in chronic skin diseasebiospace · 2d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that